Who founded Orbus Therapeutics?

Orbus Therapeutics was founded by Jason Levin in 2012.

Who are Orbus Therapeutics's investors?

Orbus Therapeutics's investors include H.I.G. Capital, H.I.G. HealthBridge Partners, Longitude Capital, Agent Capital.

How much funding has Orbus Therapeutics raised?

Orbus Therapeutics has disclosed $46.5M raised across 3 rounds.

Where is Orbus Therapeutics headquartered?

Orbus Therapeutics is headquartered in Aptos, US.

Orbus Therapeutics

Aptos, US · Founded 2012 · 4 known investors

Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.

Biotech Healthtech

Founders & leadership

Orbus Therapeutics was founded in 2012 by Jason Levin.

Jason LevinFounder, Director and Chief Executive Officer

Jason D. LevinExecutive

Robert M. MyersExecutive

Board

Michael WassermanBoard director

Patrick EnrightBoard director

Elisha (Terry) GouldBoard director

Ernest MarioBoard director

Investors · 4

H.I.G. CapitalMiami

H.I.G. HealthBridge PartnersMiami · $5M – $40M

Longitude CapitalMenlo Park · $10M – $30M

Agent CapitalreportedWaltham

Reported raises · per SEC filings

Form D private placements

$46.5M disclosed across 3 rounds · 2015–2020

▶$10MraisedAug 2020 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kurt von EmsterDirector
Robert M. MyersExecutive Officer, Director
Elisha (Terry) GouldDirector
Ernest MarioDirector
Patrick EnrightDirector
Jason D. LevinExecutive Officer, Director
Michael WassermanDirector

Offering amount: $27M
Amount sold: $10M
First sale: Jul 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$18.5MraisedMar 2019 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael WassermanDirector
Patrick EnrightDirector
Jason D. LevinExecutive Officer, Director
Ernest MarioDirector
Elisha (Terry) GouldDirector
Robert M. MyersExecutive Officer, Director

Offering amount: $39.5M
Amount sold: $18.5M
First sale: Aug 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$18MraisedAug 2015 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jason D. LevinExecutive Officer, Director
Ernest MarioDirector
Michael WassermanDirector
Patrick EnrightDirector
Elisha (Terry) GouldDirector
Robert M. MyersExecutive Officer, Director

Offering amount: $32.5M
Amount sold: $18M
First sale: Aug 2015
Incorporated: Corporation, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Orbus Therapeutics do?: Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.
Who founded Orbus Therapeutics?: Orbus Therapeutics was founded by Jason Levin in 2012.
Who are Orbus Therapeutics's investors?: Orbus Therapeutics's investors include H.I.G. Capital, H.I.G. HealthBridge Partners, Longitude Capital, Agent Capital.
How much funding has Orbus Therapeutics raised?: Orbus Therapeutics has disclosed $46.5M raised across 3 rounds.
Where is Orbus Therapeutics headquartered?: Orbus Therapeutics is headquartered in Aptos, US.